SCHEMBL31093704

SCHEMBL31093704

O=Cc1ccc(F)c2c1cnn2C1CCCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 4/20 0.42
▸ CYP4A11 Q02928 4/20 0.42
▸ LMNA P02545 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ RXRA P19793 1/20 0.35
▸ RXRB P28702 1/20 0.35
▸ RXRG P48443 1/20 0.35
▸ ESR1 P03372 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ ATR Q13535 6/20 0.32
▸ RET P07949 2/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ MCL1 Q07820 1/20 0.30
▸ EGFR P00533 1/20 0.30
▸ PDE9A O76083 1/20 0.30
▸ PDE1A P54750 1/20 0.30
▸ PDE1B Q01064 1/20 0.30
▸ PDE1C Q14123 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31093706 1.00 CYP4F2 (0.42) CYP4F2CYP4A11LMNAALDH1A1POLB
SCHEMBL31093707 1.00 CYP4F2 (0.42) CYP4F2CYP4A11LMNAALDH1A1POLB
SCHEMBL31093817 0.85 LMNA (0.40) CYP4F2CYP4A11LMNAALDH1A1POLB
SCHEMBL29686827 0.82 LMNA (0.45) CYP4F2CYP4A11LMNAALDH1A1POLB
SCHEMBL20324247 0.82 CYP4F2 (0.44) CYP4F2CYP4A11LMNAALDH1A1POLB
SCHEMBL24495524 0.82 LMNA (0.45) CYP4F2CYP4A11LMNAALDH1A1POLB
SCHEMBL20324226 0.82 CYP4F2 (0.44) CYP4F2CYP4A11LMNAALDH1A1POLB
SCHEMBL31014478 0.80 CYP4F2 (0.44) CYP4F2CYP4A11LMNAALDH1A1POLB
SCHEMBL27084373 0.79 CYP4F2 (0.41) CYP4F2CYP4A11LMNAALDH1A1POLB
SCHEMBL24373739 0.78 CYP4F2 (0.42) CYP4F2CYP4A11LMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078122-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-03-19 — — US disclosed
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI PHARMACEUTICAL CO LTD (JP) 2026-03-05 — — US disclosed
EP-4673436-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2026-01-07 — — EP disclosed
EP-4647424-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-11-12 — — EP disclosed
WO-2024179948-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2024-09-06 — — WO disclosed
WO-2024181437-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY 中外製薬株式会社 2024-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078122-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS PKN3, PKMYT1, IP6K3 CYP4F2 2371/4885CYP4A11 1913/4885LMNA 1004/4885
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY MYT1, NTMT1, MYL6 CYP4F2 2104/4885CYP4A11 1959/4885LMNA 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback